Isis on a roll as it signs another licence deal

12 December 2012

With the ink barely dry on its $630 million deal with Biogen Idec (The Pharma Letter December 11),
antisense specialist Isis Therapeutics has signed an agreement with AstraZeneca to develop five
cancer drugs.

Under the terms of the deal, Isis and AstraZeneca will collaborate on the development of ISIS-
STAT3Rx, a drug already in early-stage clinical testing in patients with advanced lymphomas, as well
as four other undisclosed projects.

Momentum appears to be gathering behind Isis' antisense platform as it gears up to bring the
first antisense drug to market since fomivirsen, its short-lived treatment for HIV-related infection
cytomegalovirus (CMV) retinitis which remains the only antisense drug to have been commercialized
worldwide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK